Artiva Biotherapeutics, Inc.
ARTV Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$6.16
KIRA · Stoqly’s AI analyst, in plain words
- Artiva Biotherapeutics, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Artiva Biotherapeutics, Inc. lost $83.9M in fiscal 2025.
- Free cash flow was −$79.3M in fiscal 2025, — of revenue.
Market cap
$243M
P/E
—
Revenue
$0.0M
Net income
−$83.9M
Free cash flow
−$79.3M
Operating margin
—
Artiva Biotherapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$83.9M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Artiva Biotherapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- Artiva Biotherapeutics, Inc.
- CIK
- 0001817241
Artiva Biotherapeutics, Inc. · ARTV
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $33.5M | $0.3M | $0.0M |
| Revenue growth | — | −99.3% | −100.0% |
| Operating margin | −91.6% | −26,805.6% | — |
| Net income | −$28.7M | −$65.4M | −$83.9M |
| Net margin | −85.8% | −26,045.0% | — |
| Diluted EPS | −$35.78 | −$5.81 | −$3.43 |
| Cash | |||
| Cash from operations | −$47.4M | −$55.0M | −$76.8M |
| Capital expenditure | $3.3M | $0.6M | $2.6M |
| Free cash flow | −$50.7M | −$55.7M | −$79.3M |
| FCF margin | −151.3% | −22,180.9% | — |
| Share count change | — | 1,302.6% | 117.1% |
| Debt and strength | |||
| Cash and short-term investments | $77.0M | $185M | $108M |
| Shareholders' equity | −$162M | $187M | $110M |
| Current ratio | 6.5x | 15.4x | 8.6x |
| Returns and quality | |||
| Return on equity | — | −530.9% | −56.5% |
| Return on tangible equity | — | −35.0% | −76.3% |
| Piotroski F-score | — | 2 | 1 |
| Altman Z'' | −6.7 | 8.1 | −2.3 |
Insiders bought, 12 months
$109M
7 insiders
Insiders sold, 12 months
$2.5M
5 insiders
Of sales under plans
23%
$0.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Artiva Biotherapeutics, Inc. · ARTV
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.16 a share, the company is worth $243M.
Source: SEC EDGAR XBRL filings (CIK 0001817241). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.